ELSEVIER

Brain & Development 36 (2014) 479–483

CrossMark

BRAIN & DEVELOPMENT
Official Journal of the Japanese Society of Child Neurology

www.elsevier.com/locate/braindev

Original article

Carnitine palmitoyltransferase 2 gene polymorphism is a genetic risk factor for sudden unexpected death in infancy

Takuma Yamamoto [a,b,*], Hidekazu Tanaka [c], Yuko Emoto [b], Takahiro Umehara [a], Yuki Fukahori [a,d], Yukiko Kuriu [b], Ryoji Matoba [b], Kazuya Ikematsu [a]

[a] *Division of Forensic Pathology and Science, Unit of Social Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University School of Medicine, Japan*

[b] *Department of Legal Medicine, Osaka University Graduate School of Medicine, Japan*

[c] *Laboratory of Pharmacology, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Japan*

[d] *Forensic Science Laboratory, Nagasaki Prefectural Police Headquarters, Japan*

Received 19 February 2013; received in revised form 26 June 2013; accepted 18 July 2013

Abstract

Rationale: Carnitine palmitoyltransferase (CPT) II is one of a pivotal enzyme in mitochondrial fatty acid oxidation, which is essential for energy production during simultaneous glucose sparing and a requirement for major energy supply, such as prolonged fasting or exercise. When infants require more energy than provided by the glycolytic system, they rely on the mitochondrial fatty acid oxidation pathway. Mutations of the *CPT2* gene have been reported to cause sudden unexpected death in infancy (SUDI). A thermolabile phenotype of a *CPT2* polymorphism (F352C) has been recently reported to reduce CPT II enzyme activity. The F352C variant results in energy crisis at high temperature and is suspected as a risk factor for acute encephalopathy. However, a relationship between *CPT2* gene polymorphism and SUDI has not been described. *Methods:* Single nucleotide polymorphisms of the *CPT2* gene were investigated among 54 SUDI cases and 200 healthy volunteers. *Results:* The frequency of the C allele was significantly higher in the SUDI group than in the control group [25.0% *vs* 16.0%, odds ratio (OR) = 1.75, 95% confidence interval (CI) = 1.05–2.92, $p = 0.030$). The frequency of the F352C homozygote was significantly higher in the SUDI group than in control group (11.1% *vs* 3.5%, OR = 3.45, 95% CI = 1.11–10.73, $p = 0.036$). *Conclusion:* The F352C *CPT2* variant might be a genetic risk factor for SUDI.
© 2013 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.

Keywords: Carnitine palmitoyltransferase II; Sudden unexpected death in infancy; Polymorphism; Metabolic crisis

1. Introduction

Mitochondrial fatty acid oxidation is essential for energy production during conditions requiring simultaneous glucose sparing and a major energy supply, such as prolonged fasting or exercise. An essential step in fatty acid oxidation is played by the carnitine palmitoyltransferase (CPT) enzyme system, which transfers long-chain fatty acids containing ⩾16 carbons (C16, C18:1, C18:2, and C18) from the cytosolic compartment to the mitochondrial matrix, where β-oxidation takes place. The CPT enzyme system consists of several mitochondrial membrane-bound enzymes: CPT I, CPT II (EC 2.3.1.21), and carnitine–acylcarnitine translocase. CPT II is located on the inner aspect of the inner mitochondrial membrane and converts long-chain acylcarnitines to long-chain acyl-CoAs [1–3].

* Corresponding author. Address: Division of Forensic Pathology and Science, Unit of Social Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki, Nagasaki 852-8523, Japan. Tel.: +81 95 819 7076; fax: +81 95 819 7078.

E-mail address: t-yamamoto@nagasaki-u.ac.jp (T. Yamamoto).

0387-7604/$ - see front matter © 2013 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.
http://dx.doi.org/10.1016/j.braindev.2013.07.011

Carnitine palmitoyltransferase II deficiency is one of the most common inherited metabolic disorders and is categorized into three forms: neonatal (OMIM 608836) [4], infantile (OMIM 600649) [5], and adult (OMIM 255110) [6]. The infantile form usually manifests at 6–24 months of age as recurrent attacks of hypoketotic hypoglycemia, resulting in coma and seizures, liver failure, and transient hepatomegaly. About half of cases have heart involvement with cardiomyopathy and arrhythmia, and some result in sudden unexpected death in infancy (SUDI). The neonatal form is more severe than the infantile form. Many sudden death cases are reported, most often during the first month of life [1–3,7,8].

Various mutations of the *CPT2* gene have been reported and some of the more severe mutations are fatal [1–3]. *Carnitine palmitoyltransferase 2* gene polymorphisms have not been reported to affect enzyme activity, although a thermolabile phenotype of the *CPT2* polymorphism (F352C) has been recently reported to reduce enzyme activity at high temperature [9–11]. Shinohara et al. have reported that the F352C variant causes energy crisis at high temperature and is associated with acute encephalopathy [12]. The F352C variant is therefore a genetic risk factor for acute encephalopathy.

Various environmental and genetic risk factors have been associated with SUDI. Serotonin transporter, cardiac ion channel, autonomic nervous system, and complement or interleukin polymorphisms have been reported as genetic risk factors, while smoking, prone or side sleeping, soft bedding, and prematurity are recognized as environmental risk factors [13,14]. However, to our knowledge, a relationship between *CPT2* gene polymorphism and SUDI has not been described.

Under heat stress, fasting, acidosis, or seizures, moderately reduced CPT II activity due to the F352C variant may accelerate the disease process of acute encephalopathy [11]. Therefore, infants who have the F352C variant may be more vulnerable to energy crisis than those without the polymorphism, leading to a hypothetical risk of SUDI.

In the present study, we conducted a single nucleotide polymorphism (SNP) analysis of the *CPT2* gene among the SUDI group in order to determine whether the F352C variant might be a genetic risk factor for SUDI or not.

2. Materials and methods

This study was approved by the Ethics Committee of the Nagasaki University Graduate School of Medicine and Osaka University Graduate School of Medicine.

2.1. Study population

We retrospectively reviewed 54 SUDI cases at ages ranging from 1 day to 10 months (30 male; 24 female), whose causes of death were unexplained after thorough autopsies. We excluded apparent congenital abnormality and traumatic death cases.

2.2. Extraction of genomic DNA and polymorphism analysis

Genomic DNA was purified from frozen blood samples with the PureLink™ Genomic DNA kit (Invitrogen, Grand Island, NY) according to the manufacturer's instructions. Exon 4 of the *CPT2* gene was then amplified, followed by polymerase chain reaction (PCR) reactions performed in a 25-μL volume containing 12.5 μL of PrimeSTAR Max Premix (2×) (Takara, Otsu, Japan), 0.4 μM each of the primers (Forward; 5′-CAGTGTTCTGTCTCTGCCTA-3′, Reverse; 5′-GCCTCCTCTCTGAAACTGGA-3′), and 200 ng of template DNA under the following conditions: 98.0 °C for 1 min, 30 cycles of 98.0 °C for 10 s, 54.0 °C for 5 s, and 72.0 °C for 30 s, and finally 72.0 °C for 5 min. PCR products were sequenced with the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) on an Applied Biosystems 3730 DNA Analyzer (Applied Biosystems) according to the manufacturer's instructions. Sequences from the 5′ ends were confirmed by comparison with those from the 3′ ends at least twice independently and each sequence was compared with the standard sequence (GenBank accession number: *CPT2*: NM_000098.2).

2.3. Haplotype analysis of the CPT2 gene

When two heterozygous genotypes (c.1055T > G [p.F352C] and c.1102G > A [p.V368I]) in *CPT2* exon 4 were recognized, cloning was performed. The PCR products were amplified with a pair of primers. Next, we performed reconditioning PCR in order to avoid heteroduplexes from mixed-template PCR products [15]. After the PCR products were obtained, they were diluted 10-fold into a fresh reaction mixture of the same composition and cycled three times. The PCR products were purified from agarose gel and cloned into the pCR®-Blunt II-TOPO® vector (Invitrogen), and the resulting constructs were transformed into Competent high DH5α cells (Toyobo, Osaka, Japan). Colonies were selected and analyzed on kanamycin agar and the plasmid inserts were sequenced using the M13 Forward primer and the M13 Reverse primer (Invitrogen).

2.4. Genotyping of healthy individuals

Two hundred healthy Japanese volunteers (Non-SUDI control group, whose ages were over 20 years old) were subjected to genotyping by direct sequencing in the same manner as described above.

Download English Version:

https://daneshyari.com/en/article/3036954

Download Persian Version:

https://daneshyari.com/article/3036954

Daneshyari.com